Jared Moskowitz is having a moment on social media, and not the good kind. The Bluesky discourse around the Florida Democrat covers two distinct grievances: critics on the left are hammering him for votes they read as insufficiently progressive on ICE funding, and a separate current of anger targets him for commentary on U.S. aid to Israel. Neither faction is happy. Both are loud. And while the online argument rages, Moskowitz filed two stock trades on May 6 that are sitting in the public record, waiting for someone to notice.
What the Social Anger Is Actually About
The Bluesky posts catalogued in Moskowitz's trending spike break down cleanly into two complaints. First: his positioning on ICE. Posts from what appear to be primary-minded progressives are circulating the argument that Moskowitz has voted in ways that enable immigration enforcement they consider extreme, and that this makes him a Democrat in name only. Second: his public statements on Israel aid are drawing fire from a different corner of the left, with users calling his framing on Gaza funding infuriating at minimum.
Nine total social posts drove his trending spike. That's a small number. The content is not. Both strands touch the same nerve: the question of whether Moskowitz is running to the center fast enough to survive a primary, or slow enough to survive a general. Either way, he's generated the rarest Washington commodity right now, which is attention he didn't schedule.
Here's What Blind Trust Knows About His Financial Record
Two trades. Both filed May 6, 2026. Both in the $1,001 to $15,000 range, which is the minimum disclosure band and tells you the rough magnitude without giving you an exact figure. Moskowitz's full disclosure record at Blind Trust shows the pair clearly: a sale of Cencora ($COR) and a purchase of Gilead Sciences ($GILD), executed the same day.
Cencora is a pharmaceutical distribution giant. Gilead Sciences is a biotech with a heavy HIV and oncology portfolio. One trade out of healthcare, one trade into a different corner of healthcare. Moskowitz sits on the House Committee on Foreign Affairs and the House Committee on the Judiciary. Neither committee has jurisdiction over pharmaceutical distribution or drug development. These are floor-vote members on health legislation, not committee-level overseers of the sector. The trades carry no structural conflict angle from the committee assignments. They're just trades.
What they might reflect is a view on the sector's near-term direction. Cencora's distribution business is exposed to drug pricing policy. Gilead's pipeline runs on FDA approvals and patent protection. Swapping one for the other on the same day looks like a deliberate repositioning within healthcare, not an exit from it. Whether that read is right is a question for investors. Whether the timing is interesting is a question for readers.
The Broader Trading Record: 59 Scored Trades, 33 Winners
Blind Trust has scored 59 of Moskowitz's disclosed trades against 30-day excess returns versus the S&P 500. The record: 33 positive, 26 negative. A 56 percent hit rate. His mean 30-day alpha across all scored trades is 0.2 percent. That's essentially breakeven against the index, which is either reassuring or boring depending on your priors.
The best individual trade in the sample: a purchase of Broadcom ($AVGO) on March 31, 2026, in the $1,000 to $15,000 range, which beat the S&P 500 by 21.7 percentage points over the following 30 days. The worst: a sale of Automatic Data Processing ($ADP) on March 23, 2026, also in the $1,000 to $15,000 band, which underperformed the index by 11.6 points over the same window. He sold ADP before it ran. That happens.
The Broadcom trade carries a notation in the data: committee overlap with Technology. Moskowitz does not sit on the House Committee on Science, Space, and Technology or the House Committee on Energy and Commerce. He sits on Foreign Affairs and Judiciary. The committee overlap flag in the data appears to reflect a broader sector tagging methodology, not a formal jurisdictional match. A purchase of a chip company by a member of the Foreign Affairs Committee is a trade, not a conflict of interest. The Judiciary Committee's Crime and Federal Government Surveillance subcommittee does touch surveillance technology in a policy sense, but that's a stretch to Broadcom's core semiconductor business. Call it what it is: a good trade with no obvious COI angle.
Two American Express ($AXP) purchases on October 10, 2025, one in the $1,000 to $15,000 range and one in the $15,000 to $50,000 range, both produced 30-day alpha of 13.8 percent. Both carry a Financial Services committee overlap tag. Moskowitz does not sit on the House Financial Services Committee. Same caveat as above. Good trades. No structural conflict from his actual committee assignments.
The Votes on the Record
Moskowitz's recent floor votes are worth running through, not because any of them directly overlap with his May 6 trades, but because the vote record is part of the public portrait.
On July 14, 2026, he voted Nay on the Protecting Privacy in Purchases Act (H.R. 1181), which passed over his objection. The bill restricts how purchase data can be shared or sold. Moskowitz voted against it. His Foreign Affairs and Judiciary committee assignments give him a reasonable institutional lens on surveillance and privacy questions generally, but the bill passed and his vote didn't change the outcome.
On June 29, he voted Yea on the TRIA Program Reauthorization Act of 2026 (H.R. 7128), which extends the federal terrorism risk insurance backstop. That's a vote with real implications for insurers and commercial real estate. Moskowitz holds no disclosed positions in insurance sector equities in the recent 90-day window, so there's no trade-vote adjacency to note.
He voted Yea on the Financial Exploitation Prevention Act of 2025 (H.R. 2478) on June 25, a bill targeting financial fraud against seniors. He voted Nay on the FISA reauthorization (H.R. 9238) on June 11, which failed. The Judiciary Committee's surveillance subcommittee assignment is directly relevant to a FISA vote. He voted against extending those authorities. That's the one vote where his committee assignment and his floor position intersect clearly, and he landed on the opposition side of a bill that went down with him.
None of these votes overlap with the May 6 trade dates. The Blind Trust overlap table for Moskowitz shows zero vote-trade overlaps in the current data window. The trades and the votes are, as recorded, unconnected events.
The Candidate Math
Moskowitz is running. The Bluesky posts suggest his primary positioning is already drawing fire from the left flank of his party. The ICE funding critique and the Israel aid critique are coming from different corners but landing in the same place: a Democratic congressman who is seen by some in his base as insufficiently reliable on two of the highest-temperature issues in the current cycle.
His trading record, at 0.2 percent mean alpha over 59 scored trades, doesn't make him look like someone working a particular edge. Thirty-three wins out of 59 is a coin flip with a slight lean. The Cencora sale and Gilead purchase on May 6 are small-dollar moves in the minimum disclosure band. They're in the public record because the law requires it, not because they're remarkable by size.
What's public is public. Moskowitz is trending because his political positioning is generating friction on both the ICE and the Israel questions. His stock trades are in the disclosure system because the Stock Act exists. The two things are happening simultaneously. Whether they're related is a question neither the filings nor the roll-call can answer.
The receipts are public. Make of them what you make of them.